1. "2014"
Formats
  1. Journal Article (2603)
  2. Meeting Abstract (1417)
  3. Book Section (235)
  4. Conference Paper (23)
  5. Book Whole (16)
  6. Review (3)
Groups
  1. Department of Medicine (1584)
  2. GSK Faculty (1082)
  3. Surgery (895)
  4. Solid Tumor Oncology Division (840)
  5. Center for Hematologic Malignancies (703)
  6. Sloan Kettering Institute Faculty (672)

More Groups

People
  1. Jedd Wolchok (71)
  2. Sergio Giralt (71)
  3. Ross Levine (69)
  4. Martin Tallman (62)
  5. Michael Berger (59)
  6. Mithat Gonen (55)

More People

Years
  1. 2014 (4297)
Publications
  1. Journal of Clinical Oncology (420)
  2. Blood (228)
  3. International Journal of Radiation Oncology, Biology, Physics (131)
  4. Cancer Research (104)
  5. Modern Pathology (89)
  6. Laboratory Investigation (82)

More Publications

Publishers
  1. Elsevier Inc. (495)
  2. American Society of Clinical Oncology (446)
  3. Springer (318)
  4. Elsevier Science, Inc. (246)
  5. Nature Publishing Group (242)
  6. American Society of Hematology (230)

More Publishers

Results (4297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+urothelial cancer at high risk for recurrence
    Meeting Abstract

    Bajorin, D. F.; Gomella, L. G.; Sharma, P.; Plimack, E. R.; O'Donnell, P. H.; Hoffman-Censits, J. H.; Flaig, T. W.; Quinn, D. I.; Campogan, D.; Haynes, H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma
    Meeting Abstract

    Atkins, M. B.; Reiney, R.; Sznol, K. M.; McDermott, D. F.; Lotem, M.; Schachter, J.; Wolchok, J. D.; Urba, W. J.; Kuzel, T.; Schuchter, L. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts
    Meeting Abstract

    Atkins, M. B.; Voss, M. H.; Plimack, E. R.; Rini, B. I.; Alter, R.; Dawson, N. A.; Beck, J. T.; Bhatt, R. S.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genoine, mate-pair sequencing data
    Meeting Abstract

    Asmann, Y. W.; Wang, C.; Necala, B. M.; Chen, X. F.; Kocher, J. P. A.; Maurer, M. J.; Habermann, T. M.; Slager, S. L.; Feldman, A. L.; Dogan, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET)
    Meeting Abstract

    Asija, A.; Sama, A. R.; Casey, J.; Sendecki, J. A.; Lewis, N.; Levu, H.; Winter, J. M.; Brody, J. R.; Mitchell, E. P.; Yeo, C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Armstrong, A. J.; Tombal, B.; Sternberg, C. N.; Higano, C. S.; Rathkopf, D. E.; Loriot, Y.; Saad, F.; Joshua, A. M.; de Bono, J. S.; Venner, P. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma
    Meeting Abstract

    Ariyan, C. E.; Lefkowitz, R. A.; Panageas, K.; Callahan, M. K.; Misholy, O.; Bello, D.; Fisher, C.; Kotin, A.; Siegelbaum, R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results
    Meeting Abstract

    Antonia, S. J.; Gettinger, S. N.; Chow, L. Q. M.; Juergens, R. A.; Borghaei, H.; Shen, Y.; Harbison, C.; Chen, A. C.; Ready, N.; Rizvi, N. A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Brahmer, J. R.; Gettinger, S. N.; Chow, L. Q. M.; Juergens, R. A.; Shepherd, F. A.; Laurie, S. A.; Gerber, D. E.; Goldman, J. W.; Shen, Y.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Amin, A.; Plimack, E. R.; Infante, J. R.; Ernstoff, M. S.; Rini, B. I.; McDermott, D. F.; Knox, J. J.; Pal, S. K.; Voss, M. H.; Sharma, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save